Caladrius Biosciences, Inc. (CLBS) News
Filter CLBS News Items
CLBS News Results
|Loading, please wait...|
CLBS News Highlights
- CLBS's 30 day story count now stands at 5.
- Over the past 8 days, the trend for CLBS's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest CLBS News From Around the Web
Below are the latest news stories about CALADRIUS BIOSCIENCES INC that investors may wish to consider to help them evaluate CLBS as an investment opportunity.
NEW YORK, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the September Life Sciences Virtual Investor Conference are now available for on-demand viewing. REGISTER NOW OR LOGIN AT: https://bit.ly/3RSjiX2The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company’s resource section. Companies are accep
Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics
Company to commence trading on The Nasdaq Capital Market under Ticker Symbol “LSTA” Lisata has approximately $76 million in cash and investments following transaction close Lisata strengthens Board of Directors and Executive Leadership Team, appointing seasoned biopharmaceutical and clinical development industry executives BASKING RIDGE, N.J. and SAN DIEGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius”) and Cend Therapeutics, Inc. (“Cend”) today annou
All Merger-related proposals approved at the Annual Meeting of StockholdersBASKING RIDGE, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), announced today that, based upon the final vote count certified by the independent inspector of elections for the annual meeting of stockholders held September 13, 2022, its stockholders approved all of the merger-related proposals, including: (i) the Agreement and Plan of Merger and Reorganiz
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Virtual Investor Conference to be held on September 15th. Individual investors, institutional investors, advisors, and analysts are invited to attend this virtual event showcasing live executive presentations from companies
BASKING RIDGE, N.J., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, today announced that David J. Mazzo, PhD, President and CEO of Caladrius, will participate in the following investor events: H.C. Wainwright 24th Annual Global Investment Conference (September 12-14, 2022)Location: Lotte New York Palace Hotel in New York C
We're starting off the final trading day of the week with an overview of the biggest pre-market stock movers for Friday!
Analysts Conflicted on These Healthcare Names: Haemonetics (HAE), Caladrius Biosciences (CLBS) and Adicet Bio (ACET)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Haemonetics (HAE – Research Report), Caladrius Biosciences (CLBS – Research Report) and Adicet Bio (ACET – Research Report). Haemonetics (HAE) Needham analyst Michael Matson maintained a Hold rating on Haemonetics today. The company's shares closed last Wednesday at $73.46, close to its 52-week high of $75.34. According to TipRanks.com, Matson is a 4-star analyst with an average return of -22.6% and a 28.0% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Bioline RX Ltd Sponsored ADR, Applied Genetic Technologies, and Lineage Cell Therapeutics.
Caladrius Biosciences’ Prospective Merger Partner, Cend Therapeutics, Announces Collaboration Agreement with Roche to Evaluate CEND-1 in Combination with Immunotherapy to Treat Pancreatic Cancer
Study to be part of Roche’s Morpheus Platform designed to enable more rapid and efficient development of novel cancer immunotherapy combinations Agreement accelerated by Caladrius’ initial investment in Cend BASKING RIDGE, N.J. and SAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”) and Cend Therapeutics, Inc. (“Cend”), today announced Cend’s execution of a collaboration agreement with F. Hoffmann-La Roche Ltd. (“Roche”) to evalu
Dawson James analyst Jason Kolbert maintained a Hold rating on Caladrius Biosciences (CLBS - Research Report) on August 5. The company's shares closed last Friday at $0.51.Kolbert covers the Healthcare sector, focusing on stocks such as Sorrento Therapeutics, Can-Fite BioPharma, and Citius Pharmaceuticals. According to TipRanks, Kolbert has an average return of -0.9% and a 36.50% success rate on recommended stocks. Caladrius Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $6.00.See today’s best-performing stocks on TipRanks >>The company has a one-year high of $1.34 and a one-year low of $0.40. Currently, Caladrius Biosciences has an average volume of 164.7K.
Merger with Cend Therapeutics remains on track to close in the third quarter of 2022, subject to stockholder approval, resulting in the formation of Lisata Therapeutics Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, today reported financial results